BioSpace News Archive

Researchers at Massachusetts General Hospital have developed a deep learning model that identifies imaging biomarkers on screening mammograms to predict a patient’s risk for developing breast cancer with greater accuracy than traditional risk assessment tools.

Endomag, a breast cancer market leader and one of the UK’s fastest growing private technology businesses1, has secured £15m (~$20m) in Series D funding.

Up to one-third of adult women who sustain a non-displaced fracture to the ulna bone of the forearm may be victims of intimate partner violence, according to a study being presented at the annual meeting of the Radiological Society of North America.

Aesthetic Medical International Holdings Group Limited, a leading provider of aesthetic medical services in China, announces its unaudited financial results for the third quarter ended September 30, 2020.

Aquilion ONE / PRISM Edition Now Offers Deep Learning Spectral Capabilities for Cardiac Exams

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and webcast featuring two experts in the science and treatment of chronic graft versus host disease (cG

Cogent Biosciences, Inc. (“Cogent”) (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Brad Barnett as Chief Technology Officer (CTO).

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell 1,500,000 shares of its common stock.

Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that, further to a press release issued on November 17, 2020, the consolidation (“Consolidation”) of the Company’s issued and outstanding common shares (“Common Shares”)

GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 at 1:50 pm EST. A live audio webcast of the presentation will be available through GW’s corporate website at www.gwpharm.com in the Invest